HOME >> BIOLOGY >> NEWS
Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology

Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology Meeting

Results of Phase II studies indicate disease stabilization in patients with multiple myeloma, amyloidosis

San Francisco, CA (Dec. 2, 2000) Dendreon Corporation today announced that long-term follow-up data from Phase II trials of its therapeutic vaccine Mylovenge were presented at the American Society of Hematology Annual Meeting in San Francisco. The trials, involving patients with multiple myeloma and with amyloidosis, indicate that Mylovenge causes regression or stabilization in more than 30 percent of patients. In some patients, these benefits were found to extend more than 18 months following treatment.

Data were presented Saturday at the American Society of Hematology Annual Meeting in San Francisco by Dr. Martha Lacy of the Mayo Clinic, principal investigator of studies involving multiple myeloma and amyloidosis patients by and Dr. Malcolm MacKenzie, director of the Sacramento Medical Foundation Blood Center and principal investigator of a multi-center trial involving further patients with multiple myeloma.

In MacKenzies multicenter trial, approximately 40 percent of the 42 multiple myeloma patients evaluated have shown benefits either in terms of disease stabilization or in tumor regression. This includes six patients with decreases in serum M protein and 10 patients with disease stabilization more than six months. Four patients have been stable for more than 18 months following treatment.

In the Mayo trial of multiple myeloma patients, 17 patients were treated with Mylovenge. Clinical responses were seen in five patients, including complete or near-complete regressions. Many of these responses continued for more than one year.

In a further Mayo trial, 10 patients with amyloidosis were treated with Mylovenge. Seven had disease stabilization or regression lasting in four cases for 18 mo
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
1-Dec-2000


Page: 1 2

Related biology news :

1. Long-term effects of carbon monoxide poisoning are an autoimmune reaction
2. Long-term heart damage may result from constant confrontation and defeat
3. Long-term effects of embryo culture on behavior studied
4. Long-term natural gas supplies should meet growing demand in coming decades, study finds
5. Long-term decline of coral reef ecosystems reported
6. Long-term study of humans and deforestation in Amazon Basin gets new support
7. Long-term studies show most intersex adults happy with gender assignments at birth
8. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
9. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
10. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
11. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: